ASCO 2024 | Integrating cemiplimab + ISA101b into the treatment paradigm for recurrent HPV16 cervical cancer
Domenica Lorusso, MD, PhD, Fondazione IRCCS National Cancer Institute of Milan, Milan, Italy, discusses the potential integration of immunotherapy strategies like cemiplimab with an ISA101b vaccine into the current treatment paradigm for recurrent HPV16 cervical cancer following the clinical benefit of cemiplimab with an ISA101b vaccine in a Phase II trial (NCT04646005). This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
AC
Disclosures
Consulting or Advisory Role – AstraZeneca; Clovis Oncology; Corcept Therapeutics; Daiichi Sankyo/Lilly; Genmab; GlaxoSmithKline; Immunogen; MSD; Novartis; Novocure; Oncoinvest; PharmaMar; Seagen; Sutro Biopharma
Speakers’ Bureau – AstraZeneca; Clovis Oncology; GlaxoSmithKline; ImmunoGen; MSD; Seagen
Research Funding – Alkermes (Inst); AstraZeneca (Inst); Clovis Oncology (Inst); Clovis Oncology (Inst); Corcept Therapeutics (Inst); Genmab (Inst); GlaxoSmithKline (Inst); GlaxoSmithKline (Inst); Immunogen (Inst); Incyte (Inst); MSD (Inst); MSD (Inst); Novartis (Inst); Pharma& (Inst); PharmaMar (Inst); Roche (Inst); Seagen (Inst)
Travel, Accommodations, Expenses – AstraZeneca; Clovis Oncology; GlaxoSmithKline; Menarini
